AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02654951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Force Feedback
Description: A monitor will display the same cursors as in the visual feedback condition, however, the cursors will be completely empty and will not fill with color.~The force feedback cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. In addition, the magnitude of the cue will be proportional to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while moving the robots with the least resistance possible.
Study NCT04600830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Intervention with deep dry needling on latent myofascial trigger points (MTrPs) in gastrocnemius muscle.
Study NCT04600830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Intervention with deep dry needling on latent myofascial trigger points (MTrPs) in gastrocnemius muscle.
Study NCT02144727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D2 distal subtotal gastrectomy
Description: D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
Study NCT02144727 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D1+ distal subtotal gastrectomy
Description: D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
Study NCT03104946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mental Development Index;Auditory Brainstem Response;okineticnystagmus
Description: mental development index(MDI）\<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus
Study NCT01173497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INIPARIB + irinotecan
Description: 21 day cycle
Study NCT00964964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Insulin degludec injected s.c. (under the skin) three times weekly
Study NCT00964964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Insulin degludec injected s.c. (under the skin) once daily for one week
Study NCT00964964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo injected s.c. (under the skin) four times weekly
Study NCT03063333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coping-oriented hypnosis
Description: Hypnosis using coping-oriented suggestions based on reversal of statements from the pain catastrophizing scale plus current treatment.
Study NCT03063333 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neutral hypnosis
Description: Hypnosis using neutral suggestions plus current treatment
Study NCT01503593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcium Phosphate, Calcium Sulphate
Description: 1cc of Calcium Phosphate and 1cc of Calcium Sulphate
Study NCT02495792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback Sensor
Description: Tibia accelerometer strapped to distal tibia to detect tibial shock
Study NCT02101385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genomically Directed Monotherapy
Description: Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). The CGTB will assign therapy to each participant individually based on biomarkers/pathways identified by DNA sequencing:
Study NCT02101385 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation/Standard Therapy
Description: Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
Study NCT03480308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
Study NCT05355467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Ricovir® (tenofovir disoproxil fumarate 300 mg) 1 tablet daily. The overall treatment period is 24 weeks.
Study NCT05355467 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Historical Data
Description: Historical Data
Study NCT03480308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block
Study NCT03480308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine
Study NCT00529958 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patellar Tendon
Description: Patellar Tendon autograft
Study NCT00529958 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hamstring Tendon
Description: Quadruple Semitendinosus/Gracilis (Hamstring) Tendon Autograft
Study NCT00529958 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double-Bundle
Description: Double-Bundle Semitendinosus/Gracilis (Hamstring) Tendon Autograft
Study NCT03425669 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Stochastic Vestibular Stimulation
Description: Stochastic vestibular stimulation will be given by electric stimulation through electrodes place over the mastoid processes behind each ear. Auditory stimulation with stochastic white noise will be administrated through ear phones.
Study NCT00669279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol CR
Description: Dose titration of 20mg by mouth once daily for 1 week, then 40mg by mouth once daily for 1 week, then 80mg by mouth once daily for 2 weeks
Study NCT00669279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Dose titration of 25mg by mouth once daily for 1 week, then 50mg by mouth once daily for 1 week, then 100mg by mouth once daily for 2 weeks
Study NCT04083105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous oxide will be given prior to determine if it reduces pain from intranasal midazolam administration. Nitrous oxide is a minimal sedation drug used as an inhaled gas to reduce anxiety and produce anxiolysis and analgesia during dental procedures.
Study NCT04083105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Intranasal midazolam will be given after nitrous oxide administration.
Study NCT00066014 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant Overdenture Treatment
Description: All overdenture treatment modalities were provided to each subject using a crossover design.
Study NCT01719705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ninety minutes before surgery, the parturients receive two identical placebo capsules
Study NCT01719705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 300 mg group
Description: Ninety minutes before surgery, the parturients receive two capsules of pregabalin 150 mg
Study NCT01719705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150 mg group
Description: Ninety minutes before surgery, the parturients receive one capsule of pregabalin 150 mg and one placebo capsule
Study NCT03425669 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham stimulation
Description: Patients will receive sham stimulation in place of active vestibular stimulation.
Study NCT03425669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active medication
Description: Patients will be examined with and without medication.
Study NCT04088162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Postoperative Negative Pressure Wound Therapy KCI NANOVA
Study NCT02586376 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 0J LLLT
Description: Sham Low-Level Laser Therapy (Sham LLLT): perform with the machine off.
Study NCT00151281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEPC
Description: Induction phase (month 1-3)~• PEPC daily (prednisone 20 mg/day, cyclophosphamide 50 mg/day, etoposide 50 mg/day, and procarbazine 50 mg/day) until expected drop in neutrophil count (ANC \< 3000), unless due to disease. After ANC returns to above 2,000/ul, PEPC resumes at alternate day or fractionated weekly basis.~Maintenance phase (month 4-12) • PEPC QOD or fractionated weekly basis.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• PEPC QOD or fractionated weekly basis
Study NCT02586376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4J LLLT
Description: 4J Low-Level Laser Therapy (4J LLLT) irradiation will be perform with 4J.
Study NCT02586376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6J LLLT
Description: 6J Low-Level Laser Therapy (6J LLLT) irradiation will be perform with 6J.
Study NCT02586376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8J LLLT
Description: 8J Low-Level Laser Therapy (8J LLLT) irradiation will be perform with 8J.
Study NCT04021966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal laser application
Description: One laser treatment cycle consists of 3 vaginal laser applications with a 4-weeks interval. Each application lasts around 5 minutes.~The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~A vaginal probe will be gently inserted and manually rotated to provide a 360° treatment of the vaginal mucosa.
Study NCT04021966 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vaginal laser application
Description: One laser treatment cycle consists of 3 vaginal laser applications with a 4-weeks interval. Each application lasts around 5 minutes.~The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~A vaginal probe will be gently inserted and manually rotated to provide a 360° treatment of the vaginal mucosa.
Study NCT03301389 — intervention group
Intervention type: OTHER
Intervention: Cardiac magnetic resonance imaging
Description: The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.
Study NCT01477281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daflon
Description: Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
Study NCT01477281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venaflon (Diosmin and Hesperidin)
Description: Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
Study NCT01913301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alagebrium
Study NCT01125098 — intervention group
Intervention type: OTHER
Intervention: PRO-CT values
Description: * continue antibiotics for 10 days if a single PRO-CT value is 0.25 mcg/L or greater, that will be judged suggestive of bacterial infection~* continue antibiotics from day 3 to day 10 if one or more PRO-CT values are 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, PLUS acute respiratory failure or clinical instability~* stop antibiotics on day 3, if one or more PRO-CT values are between 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, BUT the patient has not acute respiratory failure or clinical instability~* stop antibiotics if all the PRO-CT values are \< 0.1 mcg/L or if there is a consistent trend to normalization of PRO-CT with the last value \< 0.1 mcg/L, that will be judged suggestive of absence of bacterial infection.
Study NCT02955875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Description: Outpatient drug history management, drug regimen review, patient counseling and education before and/or after physician evaluation on the day of facility visit
Study NCT03844659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Song Weightless by Marconi Union
Description: Patients will be randomized to the intervention group (the song Weightless by Marconi Union will be playing) during subjects labor epidural placement. The intervention in this study is solely the addition of music.
Study NCT03844659 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Song
Description: No song will be played during subjects labor epidural placement.
Study NCT03011203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: In session II and III participants will perform an exercise test on a bicycle inside and outside the MR scanner.
Study NCT03011203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: In session II and III participants will perform an exercise test on a bicycle inside and outside the MR scanner.
Study NCT00151281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Induction phase (month 1-3)~• Daily thalidomide at 50 mg/day for the first 8 weeks, then dose escalated as tolerated to a maximum of 100 mg/day.~Maintenance phase (month 4-12) • Daily low dose thalidomide (50-100 mg/d)~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Daily low dose thalidomide (50-100mg/d)
Study NCT00151281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction phase (month 1-3)~• Rituximab weekly x 4 (375 mg/m2/week) starting at week 1.~Maintenance phase (month 4-12) • Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months
Study NCT03342001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitonin
Description: calcitonin nasal spray
Study NCT02158689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Study NCT02158689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human menopausal gonadotropin (hMG)
Study NCT00452374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1 g/m\^2 given IV for two days (Days 2 and 3).
Study NCT00452374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 given IV for two days (Days 2 and 3).
Study NCT00452374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Starting dose of 17.5 mg/m\^2 IV for 4 days (Days 1 through 4).
Study NCT00452374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV on Day 3 of the first cycle over 4-6 hours and on Day 1 on every cycle following.
Study NCT02144766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: caudal block with 1 ml/kg of ropivacaine 0.2%
Study NCT02144766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: caudal block with 1 ml/kg of saline
Study NCT00191243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: A: second line therapy - 1000 mg/m2, IV, day 1 and day 8 q 21 days until disease progression~B: 1000 mg/m2, IV, day 1 and day 8 q 21 days, until treatment failure
Study NCT00191243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: A: 80 mg/m2, IV, q 21 days until treatment failure followed by second line single agent gemcitabine~B: 80 mg/m2, IV, q 21 days until treatment failure
Study NCT03711890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Undergo OCT
Study NCT03711890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo resection will be undertaken
Study NCT03422198 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Cuff Brachytherapy
Description: Undergo standard of care vaginal cuff brachytherapy
Study NCT03422198 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course vaginal cuff brachytherapy
Description: Undergo short course vaginal cuff brachytherapy
Study NCT04109716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy - Adolescent Skills Training
Description: This is an indicated group depression prevention consisting of 2 individual pre-group sessions, 8 weekly group session, and up to 6 individual booster sessions. IPT-AST will be delivered predominately through telehealth.
Study NCT04109716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as usual
Description: Services as usual is expected to be brief periodic sessions (in person or remote) with the school counselor or services in the community.
Study NCT02614456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon-gamma and nivolumab
Study NCT04241848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Keeogo
Description: A new and novel type of robotic-device (Keeogo, B-temia, Inc.) was developed to provide powered assistance at the knee for persons with stroke. This device provides assistance for both knee extension and knee flexion during ambulation, transfers to standing and sitting, in addition to ascending and descending stairs. As this device isn't able to fully control the movement, it requires the ability of the patient to stand and initiate stepping. The approach the Keeogo uses to monitor the desired movement in order to appropriately provide assistance. This promotes intuitive learning for the user, minimizing the amount of instruction and practice needed to effectively ambulate allowing users to independently ambulate within one session. This device does not restrict leg movement, so the user can side-step and walk backwards. However, it does not provide assistance during these movements.
Study NCT04241848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambulation training
Description: Ambulation training will consist of mobility activities affecting daily life including: walking; squatting (or getting in and out of a chair); bending, kneeling or stooping (for picking an item up off of the floor); and ascending and descending stairs. Sessions will be monitored and tailored to the individual, based on their functional ability and to ensure their safety.
Study NCT04241848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulation training
Description: Ambulation training will consist of mobility activities affecting daily life including: walking; squatting (or getting in and out of a chair); bending, kneeling or stooping (for picking an item up off of the floor); and ascending and descending stairs. Sessions will be monitored and tailored to the individual, based on their functional ability and to ensure their safety.
Study NCT03670966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Description: Given via infusion
Study NCT03670966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03670966 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT03670966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC transplantation
Study NCT03670966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation
Description: Undergo bone marrow transplant
Study NCT03670966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT03670966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Granulocyte Colony-Stimulating Factor
Description: Given IV or SC
Study NCT03670966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT03670966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT03670966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow biopsy and aspiration
Study NCT03670966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02979405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: prophylactic infusion of phenylephrine 40 mcg/min
Study NCT02979405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phenylephrine
Description: prophylactic infusion of phenylephrine 40 mcg/min
Study NCT01149577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 06 weeks treatment with Olanzapine in a flexible dosage schedule.
Study NCT01428232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: implementation of the Baby-Friendly Hospital Initiative
Description: Implementation of BFHI steps 1-9 in maternities